en ENGLISH
eISSN: 2300-8660
ISSN: 0031-3939
Pediatria Polska - Polish Journal of Paediatrics
Bieżący numer Archiwum Artykuły zaakceptowane O czasopiśmie Rada naukowa Bazy indeksacyjne Kontakt Zasady publikacji prac Standardy etyczne i procedury
Panel Redakcyjny
Zgłaszanie i recenzowanie prac online
SCImago Journal & Country Rank
2/2022
vol. 97
 
Poleć ten artykuł:
Udostępnij:
streszczenie artykułu:
Artykuł specjalny

Guidelines for immunization of children following multisystem inflammatory syndrome in children

Kamila Maria Ludwikowska
1
,
Magdalena Okarska-Napierała
2
,
Agnieszka Matkowska-Kocjan
1
,
Teresa Jackowska
3
,
Jacek Wysocki
4, 5
,
Ernest Kuchar
2
,
Jarosław Peregud-Pogorzelski
6
,
Leszek Szenborn
1

  1. Department of Pediatric Infectious Diseases, Wroclaw Medical University, Wroclaw, Poland
  2. Department of Pediatrics with Clinical Assessment Unit, Medical University of Warsaw, Warsaw, Poland
  3. Department of Pediatrics, Medical Centre of Postgraduate Education, Warsaw, Poland
  4. Department of Preventive Medicine, Poznan University of Medical Sciences, Poznan, Poland
  5. 2nd Department of Infectious Diseases, Children’s Hospital in Poznan, Poznan, Poland
  6. Department of Pediatrics, Pediatric Oncology and Immunology, Pomeranian Medical University, Szczecin, Poland
Pediatr Pol 2022; 97 (2): 81-88
Data publikacji online: 2022/06/10
Pełna treść artykułu Pobierz cytowanie
 
Metryki PlumX:


Multisystem inflammatory syndrome in children (MIS-C) is a late complication of SARS-CoV-2 infection, either symptomatic or asymptomatic. The underlying cause is immunological dysregulation, leading to severe inflammatory processes. Children with MIS-C require hospital treatment, the use of immunomodulating drugs, and often intensive care. COVID-19 vaccination is safe and highly effective in preventing not only severe COVID-19, but also MIS-C in adolescents. However, there are no explicit vaccination recommendations for children who underwent MIS-C. We present a summary of current knowledge on vaccinations against COVID-19 in the context of MIS-C. Moreover, we propose guidance concerning vaccinations for children following MIS-C.